FULGENT GENETICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 20.35 USD | -1.12% |
|
-1.41% | -29.61% |
| 06/03 | Piper Sandler Adjusts Price Target on Fulgent Genetics to $25 From $28, Maintains Neutral Rating | MT |
| 29/02 | UBS Adjusts Fulgent Genetics Price Target to $25 From $35, Maintains Neutral Rating | MT |
| Sales 2024 * | 279M 23.31B | Sales 2025 * | 322M 26.83B | Capitalization | 615M 51.35B |
|---|---|---|---|---|---|
| Net income 2024 * | -69M -5.76B | Net income 2025 * | -58M -4.84B | EV / Sales 2024 * | -0.66 x |
| Net cash position 2024 * | 800M 66.76B | Net cash position 2025 * | 755M 62.98B | EV / Sales 2025 * | -0.43 x |
| P/E ratio 2024 * |
-8.91
x | P/E ratio 2025 * |
-10.9
x | Employees | 1,184 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 61.71% |
More Fundamentals
* Assessed data
More news
Latest transcript on Fulgent Genetics, Inc.
More recommendations
More press releases
| 1 day | -1.12% | ||
| 1 week | -1.41% | ||
| Current month | -6.22% | ||
| 1 month | -6.74% | ||
| 3 months | -18.60% | ||
| 6 months | -13.92% | ||
| Current year | -29.61% |
1 week
19.97
21.19
1 month
19.8821.89
Current year
19.8829.91
1 year
19.8844.09
3 years
19.88112.00
5 years
4.71189.89
10 years
2.73189.89
| Managers | Title | Age | Since |
|---|---|---|---|
Ming Hsieh
CEO | Chief Executive Officer | 68 | 13/16/13 |
James Xie
FOU | Founder | 58 | 13/16/13 |
Paul Kim
DFI | Director of Finance/CFO | 56 | 01/16/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Ming Hsieh
CEO | Chief Executive Officer | 68 | 13/16/13 |
Linda Marsh
BRD | Director/Board Member | 74 | 01/19/01 |
Regina Groves
BRD | Director/Board Member | 66 | 03/23/03 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.30% | 27 M€ | -6.44% | - | |
| 0.26% | 29 M€ | -5.25% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 01/24/01 | 20.35 | -1.12% | 308 788 |
| 29/24/29 | 20.58 | +2.39% | 160,662 |
| 26/24/26 | 20.1 | +0.35% | 77,988 |
| 25/24/25 | 20.03 | -3.42% | 184,148 |
| 24/24/24 | 20.74 | +0.48% | 152,597 |
Delayed Quote Nasdaq, April 01, 2024 at 01:30 am IST
More quotes
Fulgent Genetics, Inc. is a technology-based genetic company with a laboratory services business and a therapeutic development business. The Companyâs laboratory services business includes technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile (PK) profile of new and existing cancer drugs. Its technology platform for its laboratory services business includes gene probes, data suppression and comparison algorithms, learning software, and laboratory information management systems. The platform provides a test menu, the ability to rapidly develop and launch new tests and customizable test offerings. The Company also offers next-generation sequencing (NGS) services.
Calendar
03/05/2024
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
HOLD
Number of Analysts
3
Last Close Price
20.58
USD
Average target price
26.67
USD
Spread / Average Target
+29.58%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -29.61% | 615M | |
| -16.55% | 8.43B | |
| +39.49% | 3.62B | |
| -38.71% | 2.61B | |
| -8.06% | 2.48B | |
| -7.96% | 2.34B | |
| -13.97% | 1.94B | |
| -19.73% | 1.56B | |
| -40.78% | 1.26B | |
| +8.32% | 1.1B |
- Stock Market
- Equities
- FLGT Stock
